BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fakhouri F, Frémeaux-Bacchi V. Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics. Nat Rev Nephrol 2021;17:543-53. [PMID: 33953366 DOI: 10.1038/s41581-021-00424-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
Number Citing Articles
1 Fakhouri F, Schwotzer N, Golshayan D, Frémeaux-bacchi V. The rational use of complement inhibitors in kidney diseases. Kidney International Reports 2022. [DOI: 10.1016/j.ekir.2022.02.021] [Reference Citation Analysis]
2 Rodrigues EM, Ardissino G, Pintarelli G, Capone V, Mariotti J, Verna M, Bernardo ME, Faraci M, Tozzi M, Bucalossi A, Schiavello E, Biassoni V, Guidetti A, Carotti A, Facchini L, Terruzzi E, Giglio F, Zecca M, Onida F, Caroti L, Cesaro S, Consonni D, Cugno M, Porcaro L. Gene Abnormalities in Transplant Associated-Thrombotic Microangiopathy: Comparison between Recipient and Donor's DNA. Thromb Haemost 2021. [PMID: 34965590 DOI: 10.1055/s-0041-1740498] [Reference Citation Analysis]
3 Huang L, Wu W, Zhu Y, Yu H, Tang L, Fang X. Case Report: Hemophagocytic Lymphocytosis in a Patient With Glutaric Aciduria Type IIC. Front Immunol 2021;12:810677. [PMID: 35095902 DOI: 10.3389/fimmu.2021.810677] [Reference Citation Analysis]
4 Prével R, Delmas Y, Guillotin V, Gruson D, Rivière E. Complement Blockade Is a Promising Therapeutic Approach in a Subset of Critically Ill Adult Patients with Complement-Mediated Hemolytic Uremic Syndromes. J Clin Med 2022;11:790. [PMID: 35160242 DOI: 10.3390/jcm11030790] [Reference Citation Analysis]
5 Schmidt T, Gödel M, Mahmud M, Fischer L, Huber TB, Kluger MA, Grahammer F. Ravulizumab in Preemptive Living Donor Kidney Transplantation in Hereditary Atypical Hemolytic Uremic Syndrome. Transplantation Direct 2022;8:e1289. [DOI: 10.1097/txd.0000000000001289] [Reference Citation Analysis]
6 Haydock L, Garneau AP, Tremblay L, Yen HY, Gao H, Harrisson R, Isenring P. Genetic abnormalities in biopsy-proven, adult-onset hemolytic uremic syndrome and C3 glomerulopathy. J Mol Med (Berl) 2021. [PMID: 34714369 DOI: 10.1007/s00109-021-02102-1] [Reference Citation Analysis]
7 Fernandez-ruiz R, Belmont HM. The role of anti-complement therapy in lupus nephritis. Translational Research 2022. [DOI: 10.1016/j.trsl.2022.02.001] [Reference Citation Analysis]
8 Sperati CJ. How I Treat Complement-Mediated TMA. Clin J Am Soc Nephrol 2022:CJN. [PMID: 35074846 DOI: 10.2215/CJN.13581021] [Reference Citation Analysis]
9 Al-Tamimi M, Qiao J, Gardiner EE. The utility of platelet activation biomarkers in thrombotic microangiopathies. Platelets 2022;:1-9. [PMID: 35287530 DOI: 10.1080/09537104.2022.2026912] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]